Clinical Trials Browser

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

492 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04181827 2026-04-13

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 2 FDA

Plasma cell

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

Phase 3 Recruiting

500 enrolled

Plasma cell

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

864 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

614 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT05020236 2026-03-27

MAGNETISMM-5

Phase 3 Recruiting

944 enrolled

Plasma cell

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

450 enrolled

Plasma cell

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

358 enrolled

Plasma cell

Multiple Myeloma

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

380 enrolled

Plasma cell

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

795 enrolled

Plasma cell

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

Phase 3 Recruiting

508 enrolled

Plasma cell

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

Phase 3 Recruiting

410 enrolled

Plasma cell

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

28 enrolled

Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

304 enrolled 19 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

117 enrolled

Plasma cell

Multiple Myeloma

NCT06464991 2025-07-20

FUMANBA-03

Phase 3 Recruiting

240 enrolled

Plasma cell

Multiple Myeloma

NCT06508983 2025-06-27

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Phase 3 Recruiting

360 enrolled

Plasma cell

Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Plasma cell

Multiple Myeloma